Nebulised pirfenidone in non-idiopathic pulmonary fibrosis (IPF) progressive pulmonary fibrosis (PPF): first look at FVC data - Milan 2023

New strategies for therapeutic management of interstitial lung disease of known cause

Chair(s): Antoine Froidure, GEORGE MARGARITOPOULOS

Session type: Poster session

Nebulised pirfenidone in non-idiopathic pulmonary fibrosis (IPF) progressive pulmonary fibrosis (PPF): first look at FVC data

Alex West

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Clinical, demographic and functional evaluation of patients with hypersensitivity pneumonitis and their comparison based on current diagnostic criteria

Guilherme Das Posses Bridi

Poster

Abstract

Effect of vasodilator therapy on clinical and hemodynamics of patients with pulmonary arterial hypertension, connective tissue disease related pulmonary fibrosis

Khaled Saleh

Poster

Abstract

Outcomes in real-life nintedanib treatment of progressive fibrosing interstitial lung disease.

Adriana Callari

Abstract

Role of nintedanib in the treatment of progressive pulmonary fibrosis (PPF) in daily clinical practice.

Fatima Andres Franch

Poster

Abstract

Real-life analysis of adherence to antifibrotic treatment in patients with progressive pulmonary fibrosis in Romania a specialized center-based cohort study

Flavia-gabriela Martis

Poster

Abstract

Nintedanib for patients with CTD related pulmonary fibrosis: real-life data.

Eirini Vasarmidi

Poster

Abstract

Treatment and clinical course of hypersensitive pneumonitis single center experience

Goran Glodic

Poster

Abstract

Real-world data from 24 UK centres for the use of nintedanib for progressive fibrosing interstitial lung disease

Samuel Hague

Poster

Abstract

Sustained-release morphine for breathlessness in interstitial lung disease - a crossover study

Diana Ferreira

Abstract

Whole Lung Lavage for Pulmonary Alveolar Proteinosis: A Retrospective Analysis of 33 Cases

Philippe Colares

Poster

Abstract

Early intervention of antifibrotics along with anti-inflammatory treatment in rapidly progressive interstitial lung disease (RP-ILD) with anti-MDA5 antibody-positive dermatomyositis (MDA5-DM)

Tomohiro Bando

Poster

Abstract

Efficacy of mycophenolate mofetil in fibrotic hypersensitivity pneumonitis treatment

Ana Filipa Torres Silva

Poster

Abstract

Efzofitimod: a novel therapeutic candidate for SSc-ILD

Zhiwen Xu

Poster

Abstract

Real-world of Nintedanib in a Spanish non-IPF progressive pulmonary fibrosis cohort

Vanesa Vicens Zygmunt

Poster

Abstract

Progression and tolerance of patients with connective tissue disease-related interstitial lung disease (CTD-ILD) on rituximab treatment

Ana Belen Llanos Gonzalez

Poster

Abstract

Online Mindfulness-Based Interventions (MBI) for palliative care: reducing dyspnea, depression, anxiety, and stress in patients with interstitial lung disease assisted at the UFMG University Hospital

Eliane Viana Mancuzo

Poster

Abstract

Real-life multicentric national observational study of the use of nintedanib in systemic sclerosis-associated interstitial lung disease

Vincent Koether

Poster

Abstract

Impact of oxygenation strategies on outcome in acute exacerbation of interstitial lung disease : A multicenter restrospective study

Robin Thevenin

Poster

Abstract

Nebulised pirfenidone in non-idiopathic pulmonary fibrosis (IPF) progressive pulmonary fibrosis (PPF): first look at FVC data

Alex West

Poster

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}